近几年来,肾癌发病率呈持续增长趋势,传统上外科切除是治疗小肾癌的“金标准”,然而对于预期寿命较短,伴有其他合并症及肾功能受损不适合手术的患者,肾癌局部消融治疗无疑是最好的选择。近年来随着消融技术的进步和长时间的疗效随访,局部消融治疗已经取得了很好的治疗效果。由于国内许多医院都在开展或拟开展肾肿瘤冷冻消融,为提高肾肿瘤冷冻消融临床治愈率及手术安全性,需要对消融的手术适应证、禁忌证、围手术期处理、疗效评价等常见问题进行规范。在国内目前尚无肾肿瘤冷冻消融围手术期专家共识形成,为规范临床工作中肾肿瘤冷冻消融围手术期管理及相关的技术操作,提升冷冻消融的有效性和安全性,中国抗癌协会肿瘤介入与微创诊疗继续教育基地专家委员会召集相关领域专家探讨制订本共识,供临床参考应用。
In recent years, the incidence of renal cancer has been increasing continuously. Surgical resection is the “gold standard” for the treatment of small renal cancer. However, local ablation therapy of renal cancer is undoubtedly the best choice for patients with short life expectancy, other complications, and impaired renal function who are not suitable for surgery. In recent years, with the development of ablation techniques and long-term follow-up, local ablation has shown good therapeutic effects. As many domestic hospitals are performing or planning to perform renal tumor cryoablation to improve the clinical cure rate and surgical safety of renal tumor cryoablation, it is necessary to standardize the surgical indications, contraindications, perioperative management, efficacy evaluation, and other common problems. Currently, there is no expert consensus regarding perioperative renal tumor cryoablation in China. To standardize the perioperative management of renal tumor cryoablation and related technical operations in clinical practice, and improve the effectiveness and safety of cryoablation, the expert committee of Tumor Interventional and Minimally Invasive Diagnosis and Treatment Continuing Education Base of the Chinese Anti-Cancer Association convened experts in related fields to discuss and formulate this consensus, which is hereby published, for clinical reference and application.
司同国,李龙,郭志,等. 肾肿瘤冷冻消融围手术期管理中国专家共识2022版[J]. 中华内科杂志,2023,62(04):363-368.
DOI:10.3760/cma.j.cn112138-20221024-00780版权归中华医学会所有。
未经授权,不得转载、摘编本刊文章,不得使用本刊的版式设计。
除非特别声明,本刊刊出的所有文章不代表中华医学会和本刊编委会的观点。

你好,我可以帮助您更好的了解本文,请向我提问您关注的问题。